Checkpoint inhibitors and radiation treatment in Hodgkin’s lymphoma: New study concepts of the German Hodgkin Study Group;Checkpointinhibitoren und Strahlentherapie bei Hodgkin-Lymphom: Neue Studienkonzepte der Deutschen Hodgkin Studiengruppe

Strahlentherapie und Onkologie

Volumn 193, Issue 2, 2017, Pages 95-99

  Baues, C ^a   Semrau, R ^a   Gaipl, U S ^b   Brockelmann P J ^a   Rosenbrock, J ^a   Engert, A ^a   Marnitz, S ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

^b UNIVERSITY HOSPITAL ERLANGEN   (Germany)

Author keywords

Abscopal effect; Immune modulation; Organs at risk; Programmed cell death protein 1; Radio immune therapy

Indexed keywords

DACARBAZINE; DOXORUBICIN; NIVOLUMAB; PROGRAMMED DEATH 1 RECEPTOR; VINBLASTINE; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN;

CANCER COMBINATION CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CLASSICAL HODGKIN LYMPHOMA; EDITORIAL; HUMAN; IMMUNOMODULATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; PHASE 2 CLINICAL TRIAL; POSITRON EMISSION TOMOGRAPHY-COMPUTED TOMOGRAPHY; ANTAGONISTS AND INHIBITORS; CELL CYCLE CHECKPOINT; CHEMORADIOTHERAPY; DRUG EFFECTS; FORECASTING; GERMANY; HODGKIN DISEASE; IMMUNOLOGY; MOLECULARLY TARGETED THERAPY; PROCEDURES; RADIATION ONCOLOGY; RADIOIMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; TRENDS;

ANTIBODIES, MONOCLONAL; CELL CYCLE CHECKPOINTS; CHEMORADIOTHERAPY; FORECASTING; GERMANY; HODGKIN DISEASE; HUMANS; MOLECULAR TARGETED THERAPY; PROGRAMMED CELL DEATH 1 RECEPTOR; RADIATION ONCOLOGY; RADIOIMMUNOTHERAPY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME;

EID: 84990862242     PISSN: 01797158     EISSN: 1439099X     Source Type: Journal    
DOI: 10.1007/s00066-016-1050-4     Document Type: Editorial

References (23)

1. Brahmer JR, Tykodi SS, Chow LQ et al (2012) Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 366:2455–2465
2. Keir ME, Butte MJ, Freeman GJ et al (2008) PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol 26:677–704
3. Green MR, Monti S, Rodig SJ et al (2010) Integrative analysis reveals selective 9p24.1 amplification, increased PD-1 ligand expression, and further induction via JAK2 in nodular sclerosing Hodgkin lymphoma and primary mediastinal large B‑cell lymphoma. Blood 116:3268–3277
4. Ansell SM, Lesokhin AM, Borrello I et al (2015) PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. N Engl J Med 372:311–319
5. Yared JA, Hardy N, Singh Z et al (2016) Major clinical response to nivolumab in relapsed/refractory Hodgkin lymphoma after allogeneic stem cell transplantation. Bone Marrow Transplant 51:850–852
6. Derer A, Frey B, Fietkau R et al (2015) Immune-modulating properties of ionizing radiation: rationale for the treatment of cancer by combination radiotherapy and immune checkpoint inhibitors. Cancer Immunol Immunother 65:779. doi:10.1007/s00262-015-1771-8
7. Eich HT, Kriz J, Schmidberger H et al (2013) The German evidence-based guidelines for Hodgkin’s lymphoma. Aspects for radiation oncologists. Strahlenther Onkol 189:445–447
8. Gaipl US, Multhoff G, Scheithauer H et al (2014) Kill and spread the word: stimulation of antitumor immune responses in the context of radiotherapy. Immunotherapy 6:597–610
9. Multhoff G, Gaipl US, Niedermann G (2012) The role of radiotherapy in the induction of antitumor immune responses. Strahlenther Onkol 188(Suppl):312–315
10. Barker CA, Postow MA (2014) Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes. Int J Radiat Oncol Biol Phys 88:986–997
11. Stamell EF, Wolchok JD, Gnjatic S et al (2013) The abscopal effect associated with a systemic anti-melanoma immune response. Int J Radiat Oncol Biol Phys 85:293–295
12. Sharabi AB, Nirschl CJ, Kochel CM et al (2015) Stereotactic radiation therapy augments antigen-specific PD-1-mediated antitumor immune responses via cross-presentation of tumor antigen. Cancer Immunol Res 3:345–355
13. Troost EG (2016) Stereotactic radiotherapy augments the immune response. Strahlenther Onkol 192:70–71
14. Deng L, Liang H, Burnette B et al (2014) Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J Clin Invest 124:687–695
15. Behringer K, Goergen H, Hitz F et al (2015) Omission of dacarbazine or bleomycin, or both, from the ABVD regimen in treatment of early-stage favourable Hodgkin’s lymphoma (GHSG HD13): an open-label, randomised, non-inferiority trial. Lancet 385:1418–1427
16. Engert A, Plutschow A, Eich HT et al (2010) Reduced treatment intensity in patients with early-stage Hodgkin’s lymphoma. N Engl J Med 363:640–652
17. Kriz J, Spickermann M, Lehrich P et al (2015) Breath-hold technique in conventional APPA or intensity-modulated radiotherapy for Hodgkin’s lymphoma: Comparison of ILROG IS-RT and the GHSG IF-RT. Strahlenther Onkol 191:717–725
18. Hjermstad MJ, Oldervoll L, Fossa SD et al (2006) Quality of life in long-term Hodgkin’s disease survivors with chronic fatigue. Eur J Cancer 42:327–333
19. Daniels LA, Oerlemans S, Krol AD et al (2013) Persisting fatigue in Hodgkin lymphoma survivors: a systematic review. Ann Hematol 92:1023–1032
20. Raemaekers JM, Andre MP, Federico M et al (2014) Omitting radiotherapy in early positron emission tomography-negative stage I/II Hodgkin lymphoma is associated with an increased risk of early relapse: clinical results of the preplanned interim analysis of the randomized EORTC/LYSA/FIL H10 trial. J Clin Oncol 32:1188–1194
21. Kriz J, Baues C, Engenhardt-Cabillic R, et al: New Quality Assurance Program Integrating “Modern Radiotherapy” within the German Hodgkin Study Group (GHSG). Strahlenther Onkol: in press
22. Kriz J, Baues C, Engenhardt-Carbillic R, et al: Report of the Radiotherapy Panel of the German Hodgkin Study Group (GHSG): Quality Control of Involved Field Radiotherapy within the HD 13 and HD 14 trials. Strahlenther Onkol: in press
23. Krebs L, Amorin S, Brice P et al: Analyses of patterns-of-failure and prognostic factors according to radiation fields in early-stage Hodgkin lymphoma. Strahlenther Onkol: in press